ArticleNature communications2020
Comprehensive T cell repertoire characterization of non-small cell lung cancer.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
176citing papers in PubMed, 1 pooled it
13.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
176 citing papers in PubMed, 1 synthesis or guideline pooled it, 222 citations in OpenAlex.
- Adjuvant immunotherapy improves survival in completely resected stage IB-III NSCLC: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy.Nature communications · 2025Trial
- Efficacy and safety of PD-1 blockade-activated neoantigen specific cellular therapy for advanced relapsed non-small cell lung cancer.Cancer immunology, immunotherapy : CII · 2025Trial
- Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial).Nature cancer · 2025Trial
- High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC.Journal for immunotherapy of cancer · 2024Trial
- Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma.Journal for immunotherapy of cancer · 2024Trial
- The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial.Signal transduction and targeted therapy · 2024Trial
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.Nature medicine · 2021Trial
- Distinct Spatial Immune Architectures in Tumor and Tumor-Adjacent Tissues of Early-Stage Non-Small Cell Lung Cancer.bioRxiv : the preprint server for biology · 2026Article
- Single-cell profiling of natural killer/T-cell lymphoma reveals stratified immune features and potential therapeutic implications.Nature communications · 2026Article
- Peripheral T-Cell Receptor β Repertoire Dynamics Correlate with Response to Anti-PD-L1 Therapy in Non-Small Cell Lung Cancer.Cancers · 2026Article
- Unbiased avidity-based isolation of antigen-specific T cells.Journal for immunotherapy of cancer · 2026Article
- Dual-degenerate TCRs target multiple KRAS hotspot and HLA-A3 family combinations.Research square · 2026Article
- FOXM1-Specific TCR-Engineered T Cells Target Non-Small Cell Lung Cancer.Cancer immunology research · 2026Article
- Article
- LCPBert: ProtBERT-based early-stage lung cancer prediction from T cell receptor beta sequences.iScience · 2026Article
- Spatially resolved T cell receptor diversity mapping uncovers variability of the cancer immune microenvironment.EBioMedicine · 2026Article
- Accurate profiling of single-cell alternative transcript start sites by correcting RNA degradation.Nature communications · 2026Article
- Reprogramming the tumor microenvironment through vaccine strategies to improve clinical outcomes and guide future innovations.Discover oncology · 2026Review
- Unraveling the nexus: Tumor mutational burden, PD-L1 expression, and oncogenic alterations in non-small cell lung cancer cytology specimens.Cancer cytopathology · 2026Article
116 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
58 authors at 7 institutions in 1 country.
Alexandre Reuben *Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0003-4510-0382
Jiexin Zhang *Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0001-9526-6730
Shin-Heng Chiou *Institute for Immunity, Transplantation, and Infection Operations, Howard Hughes Medical Institute, 450 Serra Mall, Stanford, CA, 94305, USA.
Rachel M Gittelman *Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA, 98102, USA.
Jun LiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Won-Chul LeeDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0003-3913-8632
Junya FujimotoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Carmen BehrensDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Xiaoke LiuDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Feng WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Kelly QuekDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-8113-0944
Chunlin WangiRepertoire, Inc., 800 Hudson Way, Suite 2304, Huntsville, AL, 35806, USA.
Farrah KheradmandBaylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
Runzhe ChenDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Chi-Wan ChowDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Heather LinDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Chantale BernatchezDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Ali JalaliDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Xin HuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Chang-Jiun WuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Agda Karina EterovicDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Edwin Roger ParraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0001-9068-1636
Erik YuskoAdaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA, 98102, USA.
Ryan EmersonAdaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA, 98102, USA.
Sharon BenzenoAdaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA, 98102, USA.
Marissa VignaliAdaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA, 98102, USA.
Xifeng WuDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Yuanqing YeDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Latasha D LittleDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Curtis GumbsDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Xizeng MaoDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Xingzhi SongDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Samantha TippenDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Rebecca L ThorntonDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Tina CasconeDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Alexandra SnyderAdaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA, 98102, USA.
Jennifer A WargoDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0003-3438-7576
Roy HerbstDepartment of Medical Oncology, 333 Cedar Street, Yale Cancer Center, New Haven, CT, 06510, USA.
Stephen SwisherDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-3080-1920
Humam KadaraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Cesar MoranDepartment of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Neda KalhorDepartment of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Jianhua ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Paul ScheetDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Ara A VaporciyanDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Boris SepesiDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Don L GibbonsDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Harlan RobinsAdaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA, 98102, USA.
Patrick HwuDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
John V HeymachDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Padmanee SharmaDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
James P AllisonDepartment of Immunology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Veera BaladandayuthapaniDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Jack J LeeDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0001-5469-9214
Mark M DavisDepartment of Microbiology and Immunology, Howard Hughes Medical Institute, Stanford, 450 Serra Mall, Stanford, CA, 94305, USA. mmdavis@stanford.edu.ORCID http://orcid.org/0000-0001-6868-657X
Ignacio I WistubaDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA. iiwistuba@mdanderson.org.
P Andrew FutrealDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA. afutreal@mdanderson.org.ORCID http://orcid.org/0000-0001-8663-2671
Jianjun ZhangDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA. jzhang20@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USAdaptive Biotechnologies (United States) · USHoward Hughes Medical Institute · USBaylor College of Medicine · USiRepertoire (United States) · USNorth Seattle College · USYale Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MUNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4MThe molecular and immune evolution in the progression of lung neoplasia to invasive adenocarcinomaR01CA234629 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ZHANG, JIANJUN · 2019 to 2023
$1.8MNCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA234629
Abstract
Immunotherapy targeting T cells is increasingly utilized to treat solid tumors including non-small cell lung cancer (NSCLC). This requires a better understanding of the T cells in the lungs of patients with NSCLC. Here, we report T cell repertoire analysis in a cohort of 236 early-stage NSCLC patients. T cell repertoire attributes are associated with clinicopathologic features, mutational and immune landscape. A considerable proportion of the most prevalent T cells in tumors are also prevalent in the uninvolved tumor-adjacent lungs and appear specific to shared background mutations or viral infections. Patients with higher T cell repertoire homology between the tumor and uninvolved tumor-adjacent lung, suggesting a less tumor-focused T cell response, exhibit inferior survival. These findings indicate that a concise understanding of antigens and T cells in NSCLC is needed to improve therapeutic efficacy and reduce toxicity with immunotherapy, particularly adoptive T cell therapy.
Indexed as
AdultAgedCarcinoma, Non-Small-Cell LungClone CellsErbB ReceptorsFemaleHumansLungLung NeoplasmsLymphocyte ActivationLymphocyte CountMaleMiddle AgedMutationSurvival AnalysisT-LymphocytesErbB Receptors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.